Induction of IP-10/CXCL10 secretion as an immunomodulatory effect of low-dose adjuvant interferon-alpha during treatment of melanoma

Immunobiology. 2010;215(2):113-23. doi: 10.1016/j.imbio.2009.03.008. Epub 2009 May 17.


This study investigated the immunomodulatory effects of low-dose interferon-alpha (IFN-alpha) in a cohort of 21 stage II or III melanoma patients treated in an adjuvant setting. Serial assessments in peripheral blood were performed at baseline and at regular intervals. Depletion of CD3+CD4+ T cells was predominant within the "central memory" and "memory" subsets. The impact of IFN-alpha was more marked at the level of all CD3+CD8+ T-cell subsets that showed a sustained and significant decrease. Both myeloid and plasmacytoid dendritic cell (DC) subsets were depleted, but the MDC/PDC ratio tended to increase 12 months after treatment. Also, CD14+CD16+ monocytes showed a significant increase of both MHC class I and the CD86 costimulatory molecule. IP-10/CXCL10 plasma levels significantly increased already at 3 months of therapy and remained at significantly high levels during the study period. The dramatic increase of IP-10/CXCL10 inversely correlated with a significant decrease of the CXCR3+CD8+ T lymphocytes. Low-dose IFN-alpha therapy can significantly affect phenotypic and functional properties of blood circulating lymphocytes and antigen-presenting cells, and production of IP-10/CXCL10, that appear to be important for the orchestration of an effective immune response during adjuvant IFN-alpha therapy for melanoma.

Publication types

  • Clinical Trial, Phase III
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / administration & dosage
  • Adjuvants, Immunologic / therapeutic use
  • Adult
  • Aged
  • CD3 Complex / immunology
  • Chemokine CXCL10 / blood*
  • Cohort Studies
  • Female
  • France
  • Humans
  • Immunomodulation*
  • Interferon alpha-2
  • Interferon-alpha / administration & dosage*
  • Lymphocyte Count
  • Male
  • Melanoma / drug therapy*
  • Melanoma / pathology
  • Middle Aged
  • Neoplasm Staging
  • Polyethylene Glycols / administration & dosage*
  • Receptors, CXCR3 / immunology
  • Recombinant Proteins
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / pathology
  • T-Lymphocyte Subsets / immunology


  • Adjuvants, Immunologic
  • CD3 Complex
  • CXCR3 protein, human
  • Chemokine CXCL10
  • Interferon alpha-2
  • Interferon-alpha
  • Receptors, CXCR3
  • Recombinant Proteins
  • Polyethylene Glycols
  • peginterferon alfa-2b